Patient presents with concerns regarding prostate health, including symptoms such as frequent urination, nocturia, weak urinary stream, hesitancy, straining to void, and intermittent hematuria.  Differential diagnosis includes benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer.  Digital rectal examination (DRE) revealed an enlarged prostate with an area of induration suspicious for malignancy.  Prostate-specific antigen (PSA) levels are elevated at [insert value] ngmL.  Transrectal ultrasound (TRUS) guided biopsy of the prostate was performed, and pathology confirmed adenocarcinoma of the prostate.  Gleason score is [insert Gleason score], indicating [insert grade, e.g., low, intermediate, or high] grade prostate cancer.  Staging workup, including bone scan and CT scan of the abdomen and pelvis, is pending to assess for metastatic disease.  The patient has been counseled on treatment options, including active surveillance, radical prostatectomy, radiation therapy (external beam radiation therapy and brachytherapy), hormone therapy (androgen deprivation therapy), and chemotherapy.  Treatment decisions will be made based on the final staging, patient preferences, and overall health status.  ICD-10 code C61.9 (Malignant neoplasm of prostate, unspecified) and relevant CPT codes for the biopsy and imaging studies are documented.  Follow-up appointment scheduled to discuss treatment plan and address any patient questions regarding prostate cancer diagnosis, prognosis, and management.